US-based pharmaceutical startup Cleave Biosciences secured $42m of series A funding on Tuesday from investors including Astellas Venture Management, the corporate venturing division of Japan-based pharmaceutical corporation Astellas. Also participating were venture capital firms US Venture Partners, 5AM Ventures and Clarus Ventures, and investment firm OrbiMed Advisors. Cleave was set up to discover cancer treatments…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
